Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 21;50:111–121. doi: 10.1016/j.ebiom.2019.11.004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 1 — Hydroxyurea (HU) induces molecular response and suppresses the T315I-positive sub-clone(s) in advanced CML. Four heavily pretreated CML patients (#1–#4) were treated with HU, BCR-ABL1 tyrosine kinase inhibitors (imatinib, 400 mg/day; dasatinib, 100 mg/day; nilotinib, 2 × 400 mg/day per os), polychemotherapy, or hematopoietic stem cell transplantation (HSCT) as indicated. The percentage of BCR-ABL1 mRNA relative to ABL1 mRNA (according to the international scale) as well as the percentage of BCR-ABL1^T315I mRNA relative to BCR-ABL1 mRNA (BCR-ABL1^T315I/BCR-ABL1, determined by ligase-dependent PCR) are shown in the upper panels. The white blood count (WBC) of the same patients are shown in the lower panels. 3 + 7: combined chemotherapy following the 3 + 7-protocol consisting of daunorubicine (60 mg/m² per day, days 1–3) and cytosine arabinoside (200 mg/m² per day, days 1–7).